HIV

Grindr Partners with Burnett Foundation Aotearoa to Offer Free At-Home HIV Test Kits to Grindr Users Throughout New Zealand

Retrieved on: 
Sunday, March 24, 2024
Men, Software, Human Resources, Networks, Medical Devices, Infectious Diseases, Consumer, Foundation, Professional Services, Philanthropy, Technology, LGBTQ+, Mobile, Wireless, Medical Supplies, General Health, Marketing, Health, Communications, Online, Equality, Partnership, HIV, Education, Public, Transport, Inc., Movement, Mobile phone

(NYSE: GRND), the world’s largest social network for the LGBTQ+ community, today announced the launch of its new partnership with Burnett Found ation Aotearoa to offer free HIV self-test kits to Grindr users throughout New Zealand.

Key Points: 
  • (NYSE: GRND), the world’s largest social network for the LGBTQ+ community, today announced the launch of its new partnership with Burnett Found ation Aotearoa to offer free HIV self-test kits to Grindr users throughout New Zealand.
  • As of today, Grindr users in New Zealand can order free HIV self-test kits through Burnett Foundation directly from links embedded in the Grindr app in less than one minute.
  • Now, Grindr users in New Zealand will be able to order these kits directly through the Grindr app around the clock.
  • Through Grindr’s partnership with Burnett Foundation, New Zealand becomes the fourth country in which users can order free HIV self-test kits directly through the Grindr app.

Yes! We Can End TB & AIDS, Says AHF

Retrieved on: 
Friday, March 22, 2024
White House, Federal Government, Public Policy, Other Health, General Health, Women, Philanthropy, Advocacy Group Opinion, Infectious Diseases, Government, Men, LGBTQ+, Foundation, Other Philanthropy, AIDS, Consumer, Health, Coinfection, AIDS Healthcare Foundation, Tuberculosis, World Tuberculosis Day, HIV, Global health, Education, Death, Infection, World Health Organization, Multidrug-resistant tuberculosis, TB, MDR-TB, AHF, Multimedia, Pharmaceutical industry

We Can End TB & AIDS’ commemorations to honor the millions of lives lost to TB while urging leaders at all levels of government to prioritize TB prevention, testing, and treatment efforts.

Key Points: 
  • We Can End TB & AIDS’ commemorations to honor the millions of lives lost to TB while urging leaders at all levels of government to prioritize TB prevention, testing, and treatment efforts.
  • View the full release here: https://www.businesswire.com/news/home/20240322482439/en/
    AIDS Healthcare Foundation (AHF) country teams, which have prioritized screening for TB in clinics—along with preventing and treating HIV/TB co-infection—will hold World TB Day commemorations around the globe.
  • Integrating TB prevention and care into HIV programs, which AHF has done, is essential for comprehensive healthcare.
  • We Can End TB & AIDS.’”
    According to the World Health Organization, TB claimed 1.3 million lives in 2022, including 167,000 people living with HIV, with an estimated nearly 11 million people falling ill to TB worldwide.

NOWDiagnostics Welcomes Dr. Stephen S. Tang as Chairman of the Board

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, General Health, Other Health, Health, Medical Supplies, College, Growth, Thomas Jefferson University, OraSure Technologies, HIV, Business, University, COVID-19, Syphilis, Research, History, Humanities, MBA, OTC, POC, Chemical engineering, Multimedia, Lehigh University, FDA, University City Science Center, Population Services International, Management

NOWDiagnostics ( NOWDx ), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company’s board of directors.

Key Points: 
  • NOWDiagnostics ( NOWDx ), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company’s board of directors.
  • View the full release here: https://www.businesswire.com/news/home/20240321747977/en/
    NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire)
    Dr. Tang is a longtime veteran of the medical diagnostic industry.
  • He led OraSure Technologies, Inc. (NASDAQ: OSUR ), a pioneer and global leader in rapid at-home tests for HIV and COVID-19, for ten years as president and CEO, chairman of the board of directors, and chairman of the compensation committee.
  • “I am delighted and enthusiastic about joining the NOWDx team as their chairman of the board,” said Dr. Tang.

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Retrieved on: 
Tuesday, March 19, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Emory University, Antigen, Streptococcus, International Society, HIV, Risk, Global health, Patient, Cohort, Hospital, Merck & Co., Aes, OPA, Epidemiology, Training school (United States), PCV20, Immunoglobulin G, Attenuated vaccine, MRK, Pediatrics, CDC, Vaccination, PPSV23, Community-acquired pneumonia, Food, FDA, PDUFA, Medicine, Vaccine

V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies presented at the meeting.

Key Points: 
  • V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies presented at the meeting.
  • If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
  • Participants were enrolled based on previous pneumococcal vaccination with PPSV23, PCV15, PCV13 (pneumococcal 13-valent conjugate vaccine), PPSV23+PCV13, PCV13+PPSV23 or PCV15+PPSV23, and received either V116, PCV15 or PPSV23.
  • V116 elicited comparable immune responses to the comparator, PCV15+PPSV23, for all 13 shared serotypes and higher immune responses for the eight serotypes covered only by V116.

Aegis Life Receives Investment to Continue Development of DNA-Encoded Therapeutic Antibodies Against Infectious Diseases Using the Fusogenix PLV Platform

Retrieved on: 
Tuesday, March 19, 2024
Research, Infectious Diseases, Genetics, Biotechnology, AIDS, Health, Pharmaceutical, Other Science, Science, Cell, Bill, HIV, Patient, Viral, Mortality, PLV, Infection, Malaria, Antibody, Therapy, Multimedia, Vaccine

View the full release here: https://www.businesswire.com/news/home/20240319141319/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240319141319/en/
    Aegis will receive up to $4.45 million in funding through a convertible promissory note from the foundation’s Strategic Investment Fund for the purpose of developing DNA-based encoded neutralizing antibody therapies for infectious diseases using the Entos Fusogenix PLV platform.
  • This investment follows an initial grant from the foundation to Aegis made in June 2023 to support this collaborative development project with a focus on HIV and malaria.
  • To address this, Aegis and Entos are developing DNA-encoded antibodies using the Fusogenix PLV platform that can be administered through intramuscular injection.
  • The Fusogenix PLV is fridge-stable and can be manufactured at scale cost-effectively, making it accessible for those living in rural, remote, or infrastructure-poor regions.

‘Ask Viamo Anything’ Combines AI with Basic Mobile Calls to Bring Next Billion Online

Retrieved on: 
Friday, March 15, 2024
Technology, Mobile, Wireless, Social Media, Other Education, Professional Services, Artificial Intelligence, Telecommunications, Education, Agriculture, Communications, Internet, Socially Responsible Investing, Natural Resources, VoIP, Depression, Health, Siri, Smartphone, Sanitation, Human, Woman, Alexa, Intelligence, HIV, Male, Religion, Ageing, Unilever, UNICEF, AI, Organizational founder, Lawyer, Information services, Norm (mathematics), Water, Hygiene, ChatGPT, Snow, Renewable energy

By bringing the latest iteration of AI to some of the world’s poorest and most remote communities, ‘Ask Viamo Anything’ heralds the fastest democratisation of technology to date.

Key Points: 
  • By bringing the latest iteration of AI to some of the world’s poorest and most remote communities, ‘Ask Viamo Anything’ heralds the fastest democratisation of technology to date.
  • “Generative AI shouldn’t just help lawyers in LA do their job 10% better,” says David McAfee, the CEO and Cofounder of platform provider Viamo.
  • By using basic voice calls as the interface, the Viamo platform is accessible to more people than can currently log onto Facebook, Instagram or TikTok.
  • “Combining AI and mobile is the necessary solution to bring the next billion people online,” says McAfee.

AHF Urges Trinidad and Tobago to Sidestep Greedy GSK

Retrieved on: 
Friday, March 15, 2024
AIDS, Public Policy, Government, Health, Infectious Diseases, Advocacy Group Opinion, Pharmaceutical, ARV, GSK, HIV, COVID-19, AHF, Caribbean region of Colombia, Letter, AIDS Healthcare Foundation, Face, Biosimilar, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) is calling on the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay (dolutegravir), a GSK antiretroviral (ARV) drug that treats HIV, which currently costs 25 times more than available biosimilar generics in neighboring Caribbean countries.

Key Points: 
  • AIDS Healthcare Foundation (AHF) is calling on the government of Trinidad and Tobago to consider issuing a compulsory license for Tivicay (dolutegravir), a GSK antiretroviral (ARV) drug that treats HIV, which currently costs 25 times more than available biosimilar generics in neighboring Caribbean countries.
  • In February, AHF and the Medical Research Foundation of Trinidad & Tobago sent a letter to GSK CEO Dame Emma Walmsley, which in part stated, “We urge you to address the lack of access to the antiretroviral drug Tivicay in Trinidad due to its high cost by lowering its price in line with biosimilar generics available in the Caribbean Region – or by committing not to threaten legal action against the purchase of a generic version of Tivicay.”
    To date, GSK has yet to respond to the letter.
  • Currently, Tivicay is under patent protection in Trinidad and Tobago, and GSK has threatened legal action if the country decides to import affordable generic ARVs.
  • “As a small island nation, Trinidad and Tobago is still recovering from the economic and social consequences of COVID-19 – paying 25 times more to provide lifelong HIV treatment for its people is untenable,” said AHF President Michael Weinstein.

Protesters Keep Heat on Greedy Gilead over Price Gouging

Retrieved on: 
Wednesday, March 13, 2024
Men, General Health, Pharmaceutical, Consumer, State, Local, Infectious Diseases, Public Policy, Health Insurance, Women, AIDS, Health, Government, HIV/AIDS, Conference, AIDS Healthcare Foundation, HIV, Gilead Sciences, AHF, Multimedia, Pharmacy, Pharmaceutical industry

HIV/AIDS advocates from AIDS Healthcare Foundation (AHF) will continue their campaign of protests targeting Gilead Sciences over the company’s ongoing efforts to rack up exorbitant profits while restricting access to its lifesaving medications.

Key Points: 
  • HIV/AIDS advocates from AIDS Healthcare Foundation (AHF) will continue their campaign of protests targeting Gilead Sciences over the company’s ongoing efforts to rack up exorbitant profits while restricting access to its lifesaving medications.
  • Protesters will gather Wednesday in front of the Loews Miami Beach Hotel where executives from Gilead will be presenting at the Barclays Annual Global Health Conference.
  • View the full release here: https://www.businesswire.com/news/home/20240312694416/en/
    The group hosted a similar protest rally targeting Gilead at the Fontainebleau Miami Beach Hotel Tuesday while company executives presented during the Leerink Partners Biopharma Conference.
  • HIV/AIDS activists are also specifically targeting Gilead CEO Daniel O’Day over his February appointment as board chair for PhRMA (Pharmaceutical Research and Manufacturers of America), the cutthroat trade group representing companies in the pharmaceutical industry in the United States.

AHF Keeps Pressure on ‘Greedy Gilead’ Over Price Gouging

Retrieved on: 
Monday, March 11, 2024
Pharmaceutical, Philanthropy, Infectious Diseases, Healthcare Reform, Social Activism, Public Policy, Advocacy Group Opinion, Foundation, Communications, AIDS, Health, Government, HIV/AIDS, Conference, AIDS Healthcare Foundation, HIV, Gilead Sciences, City, AHF, Pharmacy, Pharmaceutical industry

AIDS Healthcare Foundation (AHF) advocates will rally at the Fontainebleau Miami Beach Hotel Tuesday to protest Gilead Sciences ’ ongoing efforts to rack up exorbitant profits while restricting access to lifesaving medications.

Key Points: 
  • AIDS Healthcare Foundation (AHF) advocates will rally at the Fontainebleau Miami Beach Hotel Tuesday to protest Gilead Sciences ’ ongoing efforts to rack up exorbitant profits while restricting access to lifesaving medications.
  • AHF’s sustained protests against the drug maker continue as Gilead faces legal action over its keeping safer HIV medications off the market to maximize profits.
  • “It is so sadly apropos that Gilead CEO Daniel O’Day — the poster child for PhRMA greed — also now sits atop PhRMA, the undisputed fortress of greed,” said Michael Weinstein, AHF president and cofounder.
  • Since 2021, AHF has been taking on Gilead and CEO Daniel O’Day, holding more than two dozen protests in multiple cities, including Washington, DC, Miami, Boston, and Foster City, CA at Gilead’s corporate headquarters.

RSNA: Early Coronary Disease, Impaired Heart Function Found in Asymptomatic People with HIV

Retrieved on: 
Thursday, April 4, 2024
Biomedicine, Cardiovascular disease, MRI, Coronary artery disease, HIV, Didanosine, Viral load, Education, Patient, Facial muscles, Research, Kidney, University, Death, Physical examination, NIH, Society, Life expectancy, Risk, Moyamoya disease, OAK, World Health Organization, RSNA, DRS, Heart, Radiation, Bangladesh Technical Education Board, Digestive, Synthetic control method, Health, Person, Pharmaceutical industry

OAK BROOK, Ill., April 4, 2024 /PRNewswire-PRWeb/ -- A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV. The study was published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

Key Points: 
  • A new study found increased coronary vessel wall thickness that was significantly associated with impaired diastolic function in asymptomatic, middle-aged individuals living with HIV.
  • The ability to detect early coronary artery disease in persons living with HIV and potentially prevent detrimental effects on the heart muscle is important.
  • This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function.
  • "This research shows the impact of HIV on developing subtle subclinical coronary artery disease and its effects on heart function."